Overview photography and short-term mole monitoring in patients taking a BRAF inhibitor

JAMA Dermatology

Volumn 150, Issue 9, 2014, Pages 1010-1011

  Yagerman, Sarah ^a   Flores, Eileen ^a   Busam, Klaus ^a   Lacouture, Mario ^a   Marghoob, Ashfaq A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; B RAF KINASE;

ADULT; ANATOMICAL VARIATION; CLINICAL ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EPILUMINESCENCE MICROSCOPY; FEMALE; FOLLOW UP; HUMAN; LETTER; MALE; MELANOMA; NEVUS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT MONITORING; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MIDDLE AGED; PATHOLOGY; PHOTOGRAPHY; RETROSPECTIVE STUDY; SKIN TUMOR; TIME;

FEMALE; HUMANS; MALE; MIDDLE AGED; NEVUS; PHOTOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS;

EID: 84908239326     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.10413     Document Type: Letter

References (6)

1. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
2. Su F, Viros A,Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3): 207-215.
3. Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148(10):1183-1185.
4. Marghoob AA, Malvehy J, Braun RP, eds. Atlas of Dermoscopy. 2nd ed. New York, NY: Springer-Verlag; 2012.
5. Marghoob AA, Slade J, Kopf AW, et al. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. Br J Dermatol. 1996;135(5):704-711.
6. Cebon K,Weber J, Kim K, et al. Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positivemetastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). J Clin Oncol. 2013 (suppl).